Bosis. Arterioscler Thromb Vasc Biol. 2014;34(1):16068. 9. Kumari S, Dash D. Regulation of -catenin stabilization in human platelets. Biochimie. 2013;95(6):1252257. 10. Nayak MK, Kumar K, Dash D. Regulation of proteasome activity in activated human platelets. Cell Calcium. 2011;49(four):22632. 11. Avcu F, Ural AU, Cetin T, Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res. 2008;121(four):56771. 12. Lonial S, et al. Threat elements and kinetics of thrombocytopenia connected with bortezomib for relapsed, refractory numerous myeloma. Blood. 2005;106(12):3777784. 13. Mason KD, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173186. 14. McConkey DJ. Bortezomib paradigm shift in myeloma. Blood. 2009;114(five):93132.jci.orgVolumeNumberSeptemberReseaRch aRticleberg AL, Finley D.Ethylene glycol-d4 medchemexpress The axial channel with the proteasome core particle is gated by the Rpt2 ATPase controls each substrate entry product release. Mol Cell. 2001;7(6):1143152. 22. Smith DM, Fraga H, Reis C, Kafri G, Goldberg AL. ATP binds to proteasomal ATPases in pairs with distinct functional effects, implying an ordered reaction cycle. Cell. 2011;144(four):52638. 23. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice enable the generation of lineage-restricted gene knockouts for studying megakaryocyte platelet function in vivo. Blood. 2007;109(4):1503506. 24. Galimberti S, et al. PS-341 (Bortezomib) inhibits proliferation induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res. 2008;32(1):10312. 25. Zhang Y, Wang Z, Liu DX, Pagano M, Ravid K. Ubiquitin-dependent degradation of cyclin B is accelerated in polyploid megakaryocytes. J Biol Chem. 1998;273(three):1387392. 26. Necchi V, et al. Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26related thrombo-cytopenia. Thromb Haemost. 2012;109(2):26371. 27. Murone M, Carpenter DA, de Sauvage FJ. Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells. 1998;16(1):1. 28. Bertozzi CC, Hess PR, Kahn ML. Platelets: covert regulators of lymphatic improvement. Arterioscler Thromb Vasc Biol. 2010;30(12):2368371. 29. Benezech C, et al. CLEC-2 is essential for improvement upkeep of lymph nodes. Blood. 2014;123(20):3200207. 30. Herzog BH, et al. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature. 2013;502(7469):10509. 31. Osada M, et al. Platelet activation receptor CLEC-2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, tube formation of lymphatic endothelial cells. J Biol Chem. 2012;287(26):222412252. 32. Finney BA, et al. CLEC-2 and Syk in the megakaryocytic/platelet lineage are vital for development.Intetumumab supplier Blood.PMID:23715856 2012;119(7):1747756. 33. Bertozzi CC, et al. Platelets regulate lymphatic vascular development by means of CLEC-2-SLP-76 signaling. Blood. 2010;116(four):66170. 34. Levin J, et al. Pathophysiology of thrombocytopenia and anemia in mice lacking transcription issue NF-E2. Blood. 1999;94(9):3037047. 35. Boulaftali Y, et al. Platelet ITAM signaling is vital for vascular integrity in inflammation. J Clin Invest. 2013;123(2):90816. 36. Hamilton AM, et al. Activity-dependent growth of new dendritic spines is regulated by the proteasome. Neuron. 2012;74(6):1023030. 37. Jeon CY, et al. Handle of neurite outgrowth by RhoA inactivation. J Neurochem. 2012;120(5):68498. 38. Foulks JM, et al. PAF-a.
